{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:47:23Z","timestamp":1793998043540,"version":"4.8.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clml.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:49:17Z","timestamp":1786376957000},"page":"721-728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | Chronic Myeloid Leukemia in Low- and Middle-Income Countries: Increasing Access to Tyrosine Kinase Inhibitors and Supporting Treatment Free Remission"],"prefix":"10.1016","volume":"26","author":[{"given":"Pat","family":"Garcia-Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1481-8367","authenticated-orcid":false,"given":"Colin","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Annamalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.clml.2026.08.003_bib0001","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.12.11.1","article-title":"U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval","volume":"11","author":"Cohen","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clml.2026.08.003_bib0003","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.08.003_bib0004","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.08.003_bib0006","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fonc.2019.00372","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0007","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2026.08.003_bib0008","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12185-026-04184-4","article-title":"Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan","volume":"124","author":"Takahashi","year":"2026","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.08.003_bib0009","doi-asserted-by":"crossref","first-page":"580759","DOI":"10.3389\/fonc.2020.580759","article-title":"regional, and national burden of chronic myeloid leukemia, 1990-2017: a systematic analysis for the global burden of disease study","volume":"10","author":"Lin","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","article-title":"Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study","volume":"9","author":"Ning","year":"2020","journal-title":"Exp Hematol Oncol"},{"issue":"16","key":"10.1016\/j.clml.2026.08.003_bib0011","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.3390\/cancers16162838","article-title":"Global trial representation and availability of tyrosine kinase inhibitors for treatment of chronic myeloid leukemia","volume":"16","author":"Casey","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.clml.2026.08.003_bib0012","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2026.08.003_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.628744","article-title":"Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature","volume":"9","author":"Ocran Mattila","year":"2021","journal-title":"Front Public Health"},{"issue":"11","key":"10.1016\/j.clml.2026.08.003_bib0014","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1093\/annonc\/mdx521","article-title":"ESMO International Consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.08.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(22)00376-X","article-title":"Cancer medicines on the WHO model list of essential medicines: processes, challenges, and a way forward","volume":"10","author":"Jenei","year":"2022","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.clml.2026.08.003_bib0016","article-title":"Cancer care disparities: overcoming barriers to Cancer control in low- and middle-income countries","volume":"10","author":"Bamodu","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.clml.2026.08.003_bib0017","article-title":"Health-related quality of life and financial burden in Ethiopian patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: a cross-sectional study","volume":"10","author":"Tadesse","year":"2024","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0018","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JGO.2015.000570","article-title":"Novel humanitarian aid program: the Glivec International Patient Assistance Program-lessons learned from providing access to breakthrough targeted oncology treatment in low- and middle-income countries","volume":"1","author":"Garcia-Gonzalez","year":"2015","journal-title":"J Glob Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.08.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.bglo.2025.100023","article-title":"Max access solutions: an innovative model to bring life-saving medicines to low- and middle-income countries","volume":"1","author":"Cook","year":"2025","journal-title":"Blood Global Hematol"},{"key":"10.1016\/j.clml.2026.08.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100257","article-title":"The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: the Glivec International Patient Assistance Program (GIPAP)","volume":"19","author":"Umeh","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0021","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-026-01485-z","article-title":"Imatinib outcomes in chronic myeloid leukemia across diverse health care settings: a systematic review and meta-analysis","volume":"16","author":"Miranda-Galvis","year":"2026","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.08.003_bib0022","article-title":"A ten-year experience of treating chronic myeloid leukemia in rural Rwanda: outcomes and insights for a changing landscape","volume":"8","author":"Morgan","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.08.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.bglo.2026.100083","article-title":"Response rate and survival of patients with chronic-phase chronic myeloid leukemia on second-line treatment in Tanzania","volume":"2","author":"Nasser","year":"2026","journal-title":"Blood Global Hematology"},{"issue":"4","key":"10.1016\/j.clml.2026.08.003_bib0024","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.seminhematol.2023.06.002","article-title":"Setting up a network of comprehensive care for patients with chronic myeloid leukemia: lessons learned from Tanzania","volume":"60","author":"Nasser","year":"2023","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13104-024-06910-9","article-title":"Late presentation of chronic myeloid leukaemia patients in a low-income country: the prognostic implications and impact on treatment outcome","volume":"17","author":"Nelson","year":"2024","journal-title":"BMC Res Notes"},{"issue":"6","key":"10.1016\/j.clml.2026.08.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/03000605261454643","article-title":"Chronic myeloid leukemia in resource-limited settings: navigating treatment challenges amid limited tyrosine kinase inhibitor access","volume":"54","author":"Aamir","year":"2026","journal-title":"J Int Med Res"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0027","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/hematology.2019000050","article-title":"Meeting the needs of CML patients in resource-poor countries","volume":"2019","author":"Malhotra","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.clml.2026.08.003_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4314\/thrb.v18i4.3","article-title":"Complete haematological response to imatinib in chronic myeloid leukaemia patients attending the ocean road cancer institute in Tanzania","volume":"18","author":"Tebuka","year":"2016","journal-title":"Tanzan J Health Res"},{"issue":"6","key":"10.1016\/j.clml.2026.08.003_bib0029","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.08.003_bib0030","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/bloodadvances.2020002973","article-title":"Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania","volume":"5","author":"Nasser","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0031","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2021.004","article-title":"Social and financial barriers to optimum TKI treatment in patients with chronic myeloid leukemia-a knowledge-attitudes-practices study from India","volume":"13","author":"Gupta","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"10.1016\/j.clml.2026.08.003_bib0032","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/2374373517748641","article-title":"Challenges to care and medication adherence of patients with chronic myeloid leukemia in a resource limited setting: a qualitative study","volume":"5","author":"Bolarinwa","year":"2018","journal-title":"J Patient Exp"},{"issue":"2","key":"10.1016\/j.clml.2026.08.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.bglo.2026.100095","article-title":"Benefits and perils of generic drugs for hematologic neoplasms and their use in low- and middle-income countries: a narrative review","volume":"2","author":"Malhotra","year":"2026","journal-title":"Blood Global Hematol"},{"issue":"7","key":"10.1016\/j.clml.2026.08.003_bib0034","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clml.2017.05.006","article-title":"Generic Imatinib in chronic myeloid leukemia: survival of the cheapest","volume":"17","author":"Danthala","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.08.003_bib0035","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.htct.2021.10.213","article-title":"A multicenter non-inferiority study of efficacy and safety of generic imatinib In chronic myeloid leukemia: final analysis","volume":"43","author":"Pagnano","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"11","key":"10.1016\/j.clml.2026.08.003_bib0036","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.08.003_bib0037","series-title":"Adherence to Long-term Therapies: Evidence for Action","year":"2003"},{"issue":"5","key":"10.1016\/j.clml.2026.08.003_bib0038","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/bcp.15147","article-title":"Association between adherence to oral therapies in cancer patients and clinical outcome: a systematic review of the literature","volume":"88","author":"Lasala","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.clml.2026.08.003_bib0039","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.08.003_bib0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1590\/1516-3180.2014.0001306","article-title":"Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients","volume":"133","author":"Hamerschlak","year":"2015","journal-title":"Sao Paulo Med J"},{"key":"10.1016\/j.clml.2026.08.003_bib0041","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2147\/PPA.S163393","article-title":"Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey","volume":"12","author":"Lou","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.clml.2026.08.003_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213557","article-title":"Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia","volume":"14","author":"Mulu Fentie","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2026.08.003_bib0043","first-page":"1","article-title":"Variation in adherence measures to imatinib therapy","volume":"4","author":"Yanamandra","year":"2018","journal-title":"J Glob Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.08.003_bib0044","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clml.2016.02.040","article-title":"Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib","volume":"16","author":"Unnikrishnan","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.08.003_bib0045","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/PPA.S269355","article-title":"Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review","volume":"15","author":"Tan","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.clml.2026.08.003_bib0046","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/10781552211073894","article-title":"Pro-adherence complementary audiovisual educational intervention model for chronic myeloid leukemia patients treated with imatinib mesylate","volume":"29","author":"Barbosa","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.clml.2026.08.003_bib0047","first-page":"951","article-title":"The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms","volume":"25","author":"Moulin","year":"2017","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0048","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12962-021-00271-x","article-title":"Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries","volume":"19","author":"Rowley","year":"2021","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.clml.2026.08.003_bib0049","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1200\/GO.21.00058","article-title":"Spectrum of BCR-ABL mutations and treatment outcomes in Ethiopian imatinib-resistant patients with chronic myeloid leukemia","volume":"7","author":"Tadesse","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.08.003_bib0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41375-025-02852-8","article-title":"Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology","volume":"40","author":"Oehler","year":"2026","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.08.003_bib0051","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00277-023-05254-x","article-title":"Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings","volume":"102","author":"Hailu","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0052","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.clml.2026.08.003_bib0053","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.clml.2026.08.003_bib0054","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1182\/bloodadvances.2020003235","article-title":"Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel","volume":"5","author":"Pavlovsky","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.08.003_bib0055","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.htct.2022.04.002","article-title":"Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice","volume":"44","author":"Boquimpani","year":"2022","journal-title":"Hematol Transfus Cell Ther"},{"issue":"12","key":"10.1016\/j.clml.2026.08.003_bib0056","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMc2518028","article-title":"Treatment-free remission in chronic myeloid leukemia in low- and middle-income countries","volume":"394","author":"Annamalay","year":"2026","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.clml.2026.08.003_bib0057","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000042020","article-title":"Characteristics of chronic myeloid leukemia patients achieving deep molecular response in Vietnam","volume":"104","author":"Dung","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clml.2026.08.003_bib0058","article-title":"Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: results from real-world practice","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clml.2026.08.003_bib0059","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1016\/S2152-2650(22)01385-4","article-title":"CML-428 real world data of treatment free remission (TFR) in patients with chronic myeloid leukemia (CML) treated at a tertiary care oncology center in India","volume":"22","author":"Sarma","year":"2022","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/ijmr.ijmr_1090_21","article-title":"Feasibility of treatment-free remission with generic imatinib: results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study","volume":"157","author":"Goni","year":"2023","journal-title":"Indian J Med Res"},{"issue":"2","key":"10.1016\/j.clml.2026.08.003_bib0061","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ajh.27528","article-title":"Treatment-free remissions in children with chronic myeloid leukemia (CML): a prospective study from the Tata Memorial Hospital (TMH) pediatric CML (pCML) cohort","volume":"100","author":"Roy Moulik","year":"2025","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2026.08.003_bib0062","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs","volume":"34","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2026.08.003_bib0063","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13092567","article-title":"Treatment-free remission in chronic myeloid leukemia","volume":"13","author":"Bourne","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.clml.2026.08.003_bib0064","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019000120","article-title":"Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission","volume":"134","author":"Shanmuganathan","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.08.003_bib0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.47950","article-title":"Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia","volume":"6","author":"Winn","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2026.08.003_bib0066","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127530","article-title":"Financial impact of imatinib discontinuation in Brazil: a pharmoeconomic study","volume":"134","author":"Centrone","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.08.003_bib0067","first-page":"1625","article-title":"Financing strategies to facilitate access to high-cost anticancer drugs: a systematic review of the literature","volume":"11","author":"Patikorn","year":"2022","journal-title":"Int J Health Policy Manag"},{"issue":"7","key":"10.1016\/j.clml.2026.08.003_bib0068","first-page":"2281","article-title":"Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission","volume":"111","author":"Flynn","year":"2026","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:38:31Z","timestamp":1793954311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2152265026002533"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Chronic Myeloid Leukemia in Low- and Middle-Income Countries: Increasing Access to Tyrosine Kinase Inhibitors and Supporting Treatment Free Remission","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}